Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Sponsor: Amgen
A PHASE3 clinical study on Chronic Kidney Disease and Secondary Hyperparathyroidism, this trial is completed. The trial is conducted by Amgen and has accumulated 12 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
May 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Nov 2018 — May 2019 [monthly]
Completed PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aalborg, Denmark , Aarau, Switzerland , Alexandroupoli, Greece , Almada, Portugal , Alytus, Lithuania , Ankara, Turkey (Türkiye) , Arvada, United States , Athens, Greece , Aurora, United States and 151 more locations